Lactase deficiency revealed
Non-invasive rapid test to reveal lactose intolerance
A rapid and reliable combination of LAMP and Lateral Flow Assay technologies.
Developed in collaboration with Fraunhofer IZI, one of Europe’s leading applied-research institutes
Understanding our biotechnology: a diagnostic challenge
Lactose intolerance affects a significant portion of the global population according to large meta-analysis. Diagnosis remains a challenge for several reasons, most existing tests are either quite invasive or highly expensive and require highly skilled staff.
Eralydix’s solution fills the gap for a non-invasive, easy to use and rapid solution to screen lactose intolerance.
Biotechnology: A rapid test for lactose intolerance screening
Eralydix develops a innovative solution combining 2 well proven technologies LAMP (Loop-Mediated Isothermal Amplification) and LFA (Lateral Flow Assay) to reveal lactose Intolerance in 30 minutes.
Our approach is:
Rapid and easy to use
Fully non-invasive (buccal swab sample)
Significantly shorten the time from diagnosis to patient management
Advancing medical diagnostics through scientific innovation
Our solution brings strong value across multiple dimensions:
🧬 Medical value: more accurate diagnosis of lactose intolerance
🧪 Scientific relevance: leveraging genetic insights for better healthcare
🌍 Market potential: addressing a large and growing demand in diagnostic testing
Eralydix contributes to the evolution of personalized medicine.
Our biotechnology solution
Eralydix biotechnology is based on advanced genetic analysis, enabling rapid identification of lactase deficiency markers.
Our product is designed to be:
- scalable
- reliable
- compatible with modern diagnostic workflows
A better alternative to traditional diagnostic methods
Current diagnostic approaches include breath tests and empirical dietary trials, which can be unreliable or uncomfortable.
Eralydix differentiates itself by:
targeting the genetic origin of lactose intolerance
providing more accurate and consistent results
| Hydrogen H2 Breath test | Lactose tolerance test | Eralydix LAMP LactoCheck | Duodenal Lactase activity | Serum or urine gaxilose/galactose test | Genetic test | |
|---|---|---|---|---|---|---|
| Lactose challenge | YES | YES | NO | NO | YES | NO |
| Assessment of Symptoms | YES | YES | NO | YES | NO | NO |
| Test Principle | Detection of H2 in expired air (exhaled breath) after lactose challenge | Increase in plasma glucose after lactose challenge | Detection of 13910(C/T) polymorphism in Portable/Home Rapid Test | Lactose enzymatic activity in duodenal biopsy | Detection of D-xylose or Galactose (blood or urine) after lactose challenge | Detection of 13910(C/T) polymorphism in Laboratory PCR testing |
| Cost | ++ | + | + | ++++ | +++ | +++ |
| Skilled staff & Equipment | +++ | ++ | + | ++++ | ++ | +++ |
| Limitations | False negative tests by H2 non producers; False positive test in rapid transit or altered bowel anatomy | Glucose disorders and altered bowel anatomy | False negative in presence of atypical mutations | Patchy expression of lactase; should not be performed as a first-line procedure | Variable test performance in the literature. False positive in various conditions such as rapid transit and others | False negative in presence of atypical mutations |
| Invasive & side effect | Minimally invasive but strong and side effects | Minimally invasive (blood sampling) but strong and side effects | Non-invasive (buccal swab) no side effect | Highly invasive and potential side effect due to sedation or anaesthesia | Minimally invasive (blood sampling) High side effects | Minimally invasive (depend on sampling) no side effect |
| Sensitivity (literature avg) | 77–88% | 75–94% | >90% (target – not yet validated) | 95–100% | 70–90% | 90–100% |
| Specificity (literature avg) | 85–98% | 77–96% | >90% (target – not yet validated) | 95–100% | 80–95% | 95–100% |
| Cost estimation in CH | CHF 400.- incl med. visit | CHF 250.- incl med. visit | CHF 50-100.- | CHF 2'000.- | Only research purpose | CHF 400.- incl med. visit |
A partnership built on scientific rigor
Eralydix develops its rapid lactose-intolerance test in collaboration with the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig.
This co-development partnership brings independent, world-class expertise in diagnostic assay design and validation to our LAMP and lateral-flow technology.
Eralydix biotechnology FAQ
🧬 What is Eralydix?
Eralydix is a start-up that is developing our rapid test solution to accurately identify the genetic cause of lactose intolerance.
🧪 How does your lateral flow assay and LAMP test work?
Our approach is based on DNA analysis to detect lactase deficiency markers, enabling a precise and reliable diagnosis of lactose intolerance.
⚡ What makes your solution different from existing tests?
Unlike traditional diagnostic methods, our solution focuses on the genetic origin of lactose intolerance, providing faster, more accurate and non-invasive results.
🩺 What are the symptoms of lactose intolerance?
Symptoms vary from person to person and depending on age but generally involve stomach problems of varying severity. For more details and patient experiences, click on: “Individual cases” at the bottom of the page to view them.
🌍 Who can benefit from this biotechnology?
Our solution is designed for:
- healthcare professionals
- diagnostic laboratories
- research institutions
and ultimately benefits patients through improved diagnostic accuracy.
🤝 Are you looking for partners or investors?
Yes. We are actively seeking partners and investors to support the development and commercialization of our rapid lateral flow assay and LAMP testing solution.
📩 How can I get in touch?
You can contact us directly to learn more about our technology, partnership opportunities or project development.